New Project: OpenADMET

We are thrilled to announce the arrival of OpenADMET, a new hosted project here at the Open Molecular Software Foundation.

This addition marks an exciting chapter - OpenADMET aims to transform drug discovery by providing open-source tools and data to better predict drug absorption, distribution, metabolism, excretion, and toxicity. As part of the OMSF ecosystem, OpenADMET will have the resources and collaborative environment necessary to drive forward its mission of reducing the risk of adverse drug reactions through cutting-edge computational models and data.

OpenADMET’s focus on drug anti-targets positions it as a key player in preventing late-stage failures in drug development. By treating these anti-targets as primary targets, OpenADMET uses structural biology, and AI-driven models and active learning to accelerate the discovery of how to avoid drug toxicity issues, a major cost and time bottleneck in clinical trials.

This initiative arrives at a critical moment, complementing a $30.5 million federal grant recently awarded to UCSF to prevent harmful drug side effects. In partnership with Octant, which also received ARPA-H funding to accelerate this research, OpenADMET will be a key player in improving how drugs are designed and tested. Octant’s ultra-high throughput synthesis and screening capabilities will provide valuable data, which, when combined with OpenADMET’s models, will enhance drug discovery in unprecedented ways.

Leading this charge is Ryan Renslow, the newest addition to our team. Ryan's expertise and vision is crucial to this new endeavor, and as Project Director the project is in safe hands. Welcome Ryan!

We are excited to welcome OpenADMET to the OMSF community and look forward to the groundbreaking advancements that will emerge from this collaboration. For more information about how to join the team or get involved, visit openadmet.org or learn more about OMSF at omsf.io.